Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent and assent as required~* Diagnosis of MPS 1 confirmed by clinical signs and symptoms, documented fibroblast or leukocyte IDUA enzyme activity of less than 10% the lower limit of normal~* Female patients must not be pregnant, willing to utilize appropriate birth control methods and undergo pregnancy testing during the study~* if taking standard ERT, must be willing to discontinue for 1 week prior to dosing and for the study duration~Additional Inclusion Criteria, Stage 1:~* 18 years of age or older~* must have a diagnosis of Hurler-Scheie or Scheie syndrome~Additional Inclusion Criteria, Stage 2:~* 2 years of age or older (and less than 18)~* must be willing to undergo CNS testing, including assessment of CSF via lumbar puncture, MRI scans and neurocognitive testing~* must have evidence of Hurler-Scheie or Scheie with CNS involvement, as evidence by:~* score of 1 to 3 standard deviations below mean on IQ testing (i.e. IQ=55 or more) or in one domain of neuropsychological function (language, memory, non-verbal ability) OR~* documented historical evidence of a decline greater than 1 standard deviation on sequential testing, OR~* score between 0.75 and 1 standard deviation below the mean, AND cognitive deficit affects daily performance~Exclusion Criteria:~* Refusal to complete all assessments~* Pregnant or Lactating~* Received investigational drug within 1 year prior to study enrollment~* Medical condition or extenuating circumstance that, in the opinion of the investigator, may interfere with study compliance~* CSF pressure greater than 25 cm H20 (18 mm Hg)~* Known hypersensitivity to alpha-L-iduronidase (IDUA/Aldurazyme) or any components/excipients found in AGT-181~* Previous successful (engrafted) hematopoietic stem cell transplantation which has resulted in normalization of urinary glycosaminoglycans (GAGs); or major organ transplantation~* Clinically significant spinal cord compression or evidence of cervical instability (i.e. expected to require intervention during study participation)~* History of diabetes mellitus or hypoglycemia~Additional Exclusion Criteria, Stage 2:~* Has ventriculoperitoneal shunt~* IQ below 55~* Previously received AGT-181 in Stage 1 of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1 (adult) (Type: EXPERIMENTAL): AGT-181
- Stage 2 (children) (Type: EXPERIMENTAL): AGT-181

Based on this trial design, predict the completion outcome and termination type (if applicable).